Skip to main content

Table 2 Clinical and Laboratory Parameters of the Radiographic Axial Spondyloarthritis Patients and the Healthy Donors

From: Enhanced NETosis generation in radiographic axial spondyloarthritis: utility as biomarker for disease activity and anti-TNF-α therapy effectiveness

  r-axSpA patients (n = 30) Healthy Donors (n = 32) P
Clinical parameters
 Women/men, n/n 5/25 10/22 0.180
 Age, y 46.40 ± 2.45 41.06 ± 1.77 0.080
 BASDAI 4.42 ± 0.45  
 BASFI 4.73 ± 0.61  
 BASMI 3.22 ± 0.31  
 mSASSS 19.16 ± 3.86  
 Disease duration, y 13.23 ± 2.07  
 Extra-articular manifestations
 ➣ Uveitis 0/30 0/32  
 ➣ Psoriasis 0/30 0/32  
 ➣ IBD 0/30 0/32  
Laboratory parameters
 HLA-B27 (%) 26/30 (86.67%)  
 CRP, nmol/L 122.57 ± 31.38 13.62 ± 3.25 < 0.001
 ESR, mm/h 19.84 ± 4.09 7.48 ± 1.00 0.006
 TNF-α, pg/mL 10.89 ± 1.82 4.02 ± 1.20 0.021
 IL-1β, pg/mL 2.46 ± 0.22 1.57 ± 0.27 0.047
Treatments
 NSAIDs (%) 28/30 (93.33%)  
 Sulfasalazine (%) 2/30 (6.67%)  
  1. Values are presented as mean ± SEM. The data were analyzed using an Independent Samples t test or a Mann-Whitney U test to evaluate statistical significance between r-axSpA patients and healthy donors. Non-normally distributed data. BASDAI indicates Bath Ankylosing Spondylitis Disease Activity Index; BASFI, Bath Ankylosing Spondylitis Functionality Index; BASMI, Bath Ankylosing Spondylitis Metrology Index; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; HLA, human leukocyte antigen; IBD, inflammatory bowel disease; IL, interleukin; mSASSS, modified Stoke Ankylosing Spondylitis Spine Score; NSAIDs, non-steroidal anti-inflammatory drugs; r-axSpA, radiographic axial spondyloarthritis; TNF, tumor necrosis factor